ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Clinical trial NCT07007559 · RECRUITING

Trial details

NCT number: NCT07007559
Sponsor: ALX Oncology Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer, Metastatic

Start date: 2025-12-10
Primary completion: 2027-12-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.